 | | Vol. 13.20 – 3 June, 2022 |
| |
|
|
| Researchers specifically deleted androgen receptor in smooth muscle cells of the adult mouse prostate under two tumorigenic conditions, namely, the Hi-Myc genetic model and the T + E2 hormonal carcinogenesis model.
[Cell Reports] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated whether DHX9 modulated prostate cancer cell transcriptome and performed RNA-sequencing analyses upon DHX9 silencing in the androgen-responsive cell line LNCaP.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Using high-throughput circRNA sequencing, scientists previously identified 18 urine extracellular vesicle circRNAs that were increased in patients with prostate cancer compared with those with benign prostatic hyperplasia.
[Cell Death & Disease] |
|
|
|
| Investigators assessed radiosensitisation of androgen receptor (AR)-positive, estrogen receptor (ER)-positive cell lines using pharmacologic or genetic inhibition/degradation of AR and/or ER.
[British Journal of Cancer] |
|
|
|
| Both the compounds A-chitosan (Ch and B-Ch showed activity toward estrogen negative breast cancer and androgen negative prostate cancer cell lines.
[Colloids and Surfaces B-Biointerfaces] |
|
|
|
| LNCaP-LA showed X-ray resistance compared to LNCaP and sensitivity to carbon ion beams.
[Journal of Radiation Research] |
|
|
|
| A luciferase reporter assay revealed that MNX1 Antisense RNA 1 (MNX1‑AS1) could target miR‑2113 and negatively interacted with miR‑2113 in prostate cancer cells.
[Molecular Medicine Reports] |
|
|
|
| Scientists identified Gremlin1 as a ligand for fibroblast growth factor receptor 1, which promoted lineage plasticity and drove castration resistance.
[Nature Cancer] |
|  |
|
|
|
| Prostate cancer cells often exhibit alterations in DNA damage response genes including ataxia telangiectasia mutated, correlating with aggressive disease phenotype.
[International Journal of Biochemistry & Cell Biology] |
|
|
|
|
| ANGLE plc announced it has signed a master clinical study agreement with Solaris Health Holdings, LLC and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the United States.
[ANGLE plc (BioSpace)] |
|
|
|
| Janux Therapeutics, Inc. announced that the FDA has cleared the company’s investigational new drug application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer.
[Janux Therapeutics, Inc.] |
|
|
|
|
| September 11 – September 16, 2022
Ventura, California, United States |
|
|
|
|
|
| | La Jolla Institute for Immunology – La Jolla, California, United States |
|
|
|
| | German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
| | CRUK Manchester Institute – Manchester, United Kingdom |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | Marlene and Stewart Greenebaum Comprehensive Cancer Center – Baltimore, Maryland, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
